AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial
Key takeaways
- TEZSPIRE shows durable, clinically meaningful remission and symptom relief in EoE, positioning it as a breakthrough therapy in a difficult-to-treat disease.
- 64.8% histologic remission (210 mg) at week 24
- 68.9% histologic remission (420 mg) at week 24
- 3.5% remission on placebo at week 24
What happened
AstraZeneca and Amgen’s biologic therapy, TEZSPIRE (tezepelumab), met both co‑primary endpoints in the Phase III CROSSING trial for eosinophilic esophagitis (EoE). At week 24, 64.8% of patients on the 210 mg dose and 68.9% on the 420 mg dose achieved histologic remission versus only 3.5% on placebo (p<0.001). Dysphagia scores improved by 18.8 points (210 mg) and 22.0 points (420 mg) versus 14.7 points on placebo (p<0.001). These benefits were sustained through week 52, with 67.8% (210 mg) and…
Why it matters
The results demonstrate the first biologic that can reliably clear inflammation and improve swallowing symptoms in EoE patients, a disease that often resists standard therapies. Sustained remission through a full year suggests durable disease control, potentially reducing long‑term complications such as food…
Short-term and longer-term
Short-term. Over the next few weeks, watch for earnings releases and any FDA filing announcements.
Longer-term. For investors, the data suggest a strong long‑term growth catalyst in a specialty therapeutic area with limited competition.